Skip to main content

Table 3 Blood parameters and BMI at different time points

From: Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study

Variable mean ± S.D.

Nevirapine group (n = 67)

Efavirenz group (n = 68)

Baseline

6 months

24 months

Baseline

6 months

24 months

Haemoglobin, mg/dL

10.0 ± 1.9

11.8 ± 2.3

12.5 ± 2.3

10.4 ± 1.8

12.5 ± 1.3

12.7 ± 2.0

BMI, kg/m2

18.2 ± 2.7

20.4 ± 2.7

21.8 ± 2.5

18.4 ± 2.7

20.0 ± 2.3

21.0 ± 2.4

Bilirubin, mg/dL

0.6 ± 0.2

0.7 ± 0.1

0.7 ± 0.1

0.6 ± 0.2

0.7 ± 0.1

0.7 ± 0.1

SGOT, IU/L

43.9 ± 26.4

34.1 ± 9.5

31.1 ± 11.1

42.6 ± 21.9

37.5 ± 21.5

34.4 ± 19.6

SGPT, IU/L

34.1 ± 23.6

32.6 ± 11.8

31.1 ± 11.6

36.0 ± 22.2

31.6 ± 17.9

36.8 ± 40.1

  1. BMI Body mass index, SGOT Serum glutamic oxaloacetic transaminase, SGPT Serum glutamic pyruvic transaminase, IU International unit.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us